Yin-Hsi Chang

Yin-Hsi Chang

Auto-generated profile, based on publicly available information

Yin-Hsi Chang

Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in The Lancet Digital Health
Verified
Journal Article
Open access
JOJasmine Chiat Ling Ong
Jasmine Chiat Ling Ong
SCShelley Yin-Hsi Chang
Shelley Yin-Hsi Chang
WWWasswa William
Wasswa William
ABAtul J Butte
Atul J Butte
NSNigam H Shah
Nigam H Shah
DTDarren Shu Jeng Ting
Darren Shu Jeng Ting
With the rapid growth of interest in and use of large language models (LLMs) across various industries, we are facing some crucial and profound ethical concerns, especially in the medical field. The unique technical architecture and purported emergent abilities of LLMs differentiate them substantially from other artificial intelligence (AI) models and natural language processing techniques used, necessitating a nuanced understanding of LLM ethics. In this Viewpoint, we highlight ethical concerns stemming from the perspectives of users, developers, and regulators, notably focusing on data privacy and rights of use, data provenance, intellectual property contamination, and broad applications and plasticity of LLMs. A comprehensive framework and mitigating strategies will be imperative for the responsible integration of LLMs into medical practice, ensuring alignment with ethical principles and safeguarding against potential societal risks.

27 June 2024 in NEJM AI
Verified
Journal Article
Closed access
JOJasmine Chiat Ling Ong
Jasmine Chiat Ling Ong
SCShelley Yin-Hsi Chang
Shelley Yin-Hsi Chang
WWWasswa William
Wasswa William
ABAtul J Butte
Atul J Butte
NSNigam H. Shah
Nigam H. Shah
DTDarren Shu Jeng Ting
Darren Shu Jeng Ting

25 September 2024 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
YCYin‐Hsi Chang
Yin‐Hsi Chang
YYYuan‐Ming Yeh
Yuan‐Ming Yeh
CLChien‐Chung Lee
Chien‐Chung Lee
CCCheng‐Hsun Chiu
Cheng‐Hsun Chiu
HCHung-Chi Chen
Hung-Chi Chen
WWWei‐Chi Wu
Wei‐Chi Wu

7 October 2024 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
YCYin-Hsi Chang
Yin-Hsi Chang
Eugene Yu-Chuan KangEugene Yu-Chuan Kang
Eugene Yu-Chuan Kang
KCKuan-Jen Chen
Kuan-Jen Chen
Nan-Kai WangNan-Kai Wang
Nan-Kai Wang
LLLaura Liu
Laura Liu
Wei-Chi WuWei-Chi Wu
Wei-Chi Wu
Background/aims The aims of this study is to evaluate the anatomic, visual outcomes and associated prognostic factors in patients with advanced retinopathy of prematurity (ROP) following vitrectomy. Methods A retrospective cohort study of patients with ROP who underwent vitrectomy from 2005 to 2016 was conducted. All the patients had a follow-up period of at least 5 years. Univariate and multivariable logistic regression analyses were used to explore the factors related to unfavourable outcomes. Results In total, 81 eyes of 51 patients were included. The mean age at last follow-up was 10.2 years. The anatomic success rate was 96.3% (26/27) for stage 4A, 90.9% (20/22) for stage 4B and 31.3% (10/32) for stage 5 ROP (p<0.01). The mean logMAR best corrected visual acuity of the stage-4A eyes was the highest, followed by those of stage-4B and stage-5 eyes (0.8, 1.5 and 2.6 for stages 4A, 4B and 5, respectively; p<0.01). High myopia (≤ −5.0 D) was noted in 70.8% and 71.4% of stage-4A and stage-4B eyes, respectively. Cataract was the most common complication (25.9%), followed by corneal opacity (17.3%), strabismus (16.1%), and phthisis (16.1%). Stage of the disease was a poor prognostic factor in all vitrectomised eyes (p<0.01). Vitrectomy combined lensectomy was a significant predictor for poor anatomic outcomes for stage-4 eyes (p=0.03). Presence of plus disease was also a possible factor affecting the surgical outcomes. Conclusion The long-term surgical outcomes of the eyes with stage 4A and 4B ROP were favourable. Management of stage 5 ROP remained challenging.

15 March 2023 in Research Square
Verified
Preprint
Open access
PDF file
YCYin-Hsi Chang
Yin-Hsi Chang
EKEugene Yu-Chuan Kang
Eugene Yu-Chuan Kang
LLLaura Liu
Laura Liu
LJLaura A. Jenny
Laura A. Jenny
RKRin Khang
Rin Khang
Nan-Kai WangNan-Kai Wang
Nan-Kai Wang
Background: Optic atrophy-13 with retinal and foveal abnormalities (OPA13) (MIM #165510) is a mitochondrial disease in which apparent bilateral optic atrophy is present and sometimes followed by retinal pigmentary changes or photoreceptors degeneration. OPA13 is caused by heterozygous mutation in the SSBP1 gene, associated with variable mitochondrial dysfunctions. Results: We have previously reported a 16-year-old Taiwanese male diagnosed with OPA13 and SSBP1 variant c.320G>A (p.Arg107Gln) was identified by whole exon sequence (WES). This variant was assumed to be de novo since his parents were clinically unaffected. However, WES and Sanger sequencing further revealed the proband’s unaffected mother carrying the same SSBP1 variant with a 13% variant allele frequency (VAF) in her peripheral blood. That finding strongly indicates the maternal gonosomal mosaicism contributing to OPA13, which has not been reported before. Conclusions: In summary, we described the first case of OPA13 caused by maternal gonosomal mosaicism in SSBP1. Parental mosaicism could be a serious issue in OPA13 diagnosis, and appropriate genetic counseling should be considered.